title: [90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab].
abstract: Radioimmunotherapy is a new antineoplastic treatment modality combining the effects of irradiation and monoclonal antibodies. 90Y-ibritumomab tiuxetan is a monoclonal antibody directed against the CD20 antigen to which a radioactive isotope of yttrium is attached, used for treating follicular lymphomas (FL). Using this compound we treated 8 patients with FL relapsing or refractory to combinations of rituximab and chemotherapy. Severe neutropenia developed in 5, and severe thrombocytopenia and anemia in 3 patients. Serious infections developed in 2 patients, one died. Six patients responded to treatment, 4 are still in remission after a median follow-up of 15 months, 2 died of lymphoma. Best response was achieved in low-risk patients with a low tumor burden. 90Y-ibritumomab tiuxetan is an effective treatment for FL with significant hematological toxicity and a high price.
authors.affiliation: Zavod za hematologiju, Klinike za unutrasnje bolesti, KBC-a Rebro i Medicinskog fakulteta Sveucilista u Zagrebu. aurer@mef.hr
authors.forename: Igor
authors.initials: I
authors.lastname: Aurer
authors.forename: Drazen
authors.initials: D
authors.lastname: Huić
authors.forename: Marijan
authors.initials: M
authors.lastname: Zuvić
authors.forename: Mirjana
authors.initials: M
authors.lastname: Sever-Prebilić
authors.forename: Radmila
authors.initials: R
authors.lastname: Ajduković
authors.forename: Ivo
authors.initials: I
authors.lastname: Radman
authors.forename: Ljubica
authors.initials: L
authors.lastname: Skare-Librenjak
authors.forename: Slobodanka
authors.initials: S
authors.lastname: Ostojić-Kolonić
authors.forename: Boris
authors.initials: B
authors.lastname: Labar
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D004351:Drug Resistance; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000532:radiotherapy; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D000069283:Rituximab; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D015021:Yttrium Radioisotopes; D000069283:Rituximab; C422802:ibritumomab tiuxetan